Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 15;7(5):905-16.
doi: 10.3945/an.116.012187. Print 2016 Sep.

Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease

Affiliations
Free PMC article
Review

Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease

Jessay Gopuran Devassy et al. Adv Nutr. .
Free PMC article

Abstract

Alzheimer disease (AD) is becoming one of the most prevalent neurodegenerative conditions worldwide. Although the disease progression is becoming better understood, current medical interventions can only ameliorate some of the symptoms but cannot slow disease progression. Neuroinflammation plays an important role in the advancement of this disorder, and n-3 (ω-3) polyunsaturated fatty acids (PUFAs) are involved in both the reduction in and resolution of inflammation. These effects may be mediated by the anti-inflammatory and proresolving effects of bioactive lipid mediators (oxylipins) derived from n-3 PUFAs [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] in fish oil. Although interventions have generally used fish oil containing both EPA and DHA, several studies that used either EPA or DHA alone or specific oxylipins derived from these fatty acids indicate that they have distinct effects. Both DHA and EPA can reduce neuroinflammation and cognitive decline, but EPA positively influences mood disorders, whereas DHA maintains normal brain structure. Fewer studies with a plant-derived n-3 PUFA, α-linolenic acid, suggest that other n-3 PUFAs and their oxylipins also may positively affect AD. Further research identifying the unique anti-inflammatory and proresolving properties of oxylipins from individual n-3 PUFAs will enable the discovery of novel disease-management strategies in AD.

Keywords: Alzheimer disease; class switching; neuroinflammation; omega-3 fatty acids; oxylipins; polyunsaturated fatty acids; resolution of inflammation.

Conflict of interest statement

2 Author disclosures: JG Devassy, S Leng, M Gabbs, M Monirujjaman, and HM Aukema, no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Structure of ALA, EPA, and DHA. ALA, α-linolenic acid.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

MeSH terms

Grant support

Feedback